Omeros Corp. said the U.S. Food and Drug Administration approved the expanded indication of its eye drug Omidria to treat children.
Under the label expansion, newborns and patients up to 17 years old may now receive the treatment, which is used in cataract surgery or intraocular lens replacement.
The approval was granted by the FDA under priority review. The FDA also granted the drug an additional six months of U.S. market exclusivity.
